Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
LG H&H
Company facts
- Status
- KOSPI 051900 · ISIN KR7051900009
- Founded
- 2001-04-03
- CEO
- 이선주
- Headquarters
- 서울특별시 중구 후암로 98 LG서울역빌딩
- Industry
- KSIC 20422
- Fiscal year end
- 12
- Links
- Filings · DART · Quote · finance.naver.com · Website
- Source
- DART
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | 6,804,839 | 6,811,919 | 6,355,490 |
| Operating income | 486,981 | 459,046 | 170,689 |
| Net income | 163,524 | 203,888 | −85,779 |
| Total assets | 7,220,286 | 7,405,784 | 6,869,384 |
| Total liabilities | 1,671,359 | 1,719,864 | 1,299,082 |
| Total equity | 5,548,926 | 5,685,920 | 5,570,301 |
Unit: KRW million · Consolidated statements · Source DART 사업보고서
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
National R&D projects (NTIS)
3
item
512,000,000
Cumulative government R&D funding (KRW)
Largest projects
- 초임계에 의한 바이오디젤 생산기술개발 2005 · 산업자원부
- 나노 구조 template를 이용한 다공성 탄소 hollow sphere 제조 공정 개발 2003 · 과학기술부
- 라이팅, 신소재 등 컨버젼스를 활용한 Cosmetics개발 2009 · 지식경제부
Korean patent filings (KIPRIS)
No records
Papers with affiliated authors (OpenAlex)
No records
Companies in the same readouts
- Dong-A ST
- Chugai Pharmaceutical
- Eli Lilly
- Hangzhou Zhongmei Huadong
- Jiangsu Hengrui
- Eccogene
- Novo Nordisk
- Hanmi Pharmaceutical
Last updated 2026-09-21